In early 2004, GSK agreed to settle charges of consumer fraud for $2.5 million [REF].
On 12 February 2016, the UK Competition and Markets Authority imposed record fines of £45,000,000 on companies which were found to have infringed European Union and UK Competition law by entering into agreements to delay the market entry of generic versions of the drug in the United Kingdom.